Progress and prospect in the clinical translation of cancer nanomedicine / 药学学报
Acta Pharmaceutica Sinica
;
(12): 134-141, 2022.
Article
Dans Chinois
| WPRIM
| ID: wpr-913178
ABSTRACT
Nanotechnology has shown broad application prospects in the diagnosis and treatment of cancer. Currently, nearly 80 cancer nanomedicines are under clinical investigation, and many have been approved with enhanced anti-tumor efficacy and decreased side effects. However, the presence of various barriers in related basic research, process control and clinical trials lead to extremely low translation rate. From the perspective of clinical commercialization, we summarized the progress, clinical status, challenges and opportunities of cancer nanomedicine, and presented a cutting-edge prospect on the rational design of nanomedicine and clinical trial strategies.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Type d'étude:
Essai clinique contrôlé
langue:
Chinois
Texte intégral:
Acta Pharmaceutica Sinica
Année:
2022
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS